TY - JOUR
T1 - Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects
AU - Wong, Dean F.
AU - Kuwabara, Hiroto
AU - Brašić, James Robert
AU - Stock, Thomas
AU - Maini, Atul
AU - Gean, Emily G.
AU - Loebel, Antony
N1 - Funding Information:
Acknowledgements The study was sponsored by Sunovion Pharmaceuticals, Inc., Marlborough, MA. The authors wish to thank the JHU PET center, in particular Drs. Robert Dannals and Hayden Ravert and Emily Gean, Ph.D., and Maria Thomas, Ph.D., for consultation and editorial support. Lauren Sims, Johns Hopkins University study coordinator.
PY - 2013/9
Y1 - 2013/9
N2 - Rationale: A positron emission tomography (PET) study of dopamine D 2 receptor occupancy was conducted to support a rational dose selection for clinical efficacy studies with lurasidone, an atypical antipsychotic that was approved for the treatment of schizophrenia by the FDA in late 2010. Objectives: To determine the dopamine D2 receptor occupancy of lurasidone in the ventral striatum, putamen and caudate nucleus, and to characterize the relationship between lurasidone serum concentration and D2 receptor occupancy. Methods: A single oral dose of lurasidone (10, 20, 40, 60, or 80 mg) was administered sequentially to healthy male subjects (n = 4 in each cohort). Two PET scans were performed. For each scan, 20 mCi of [11C]raclopride was administered intravenously as a bolus injection, followed immediately by 90 min of PET scan acquisitions. Results: The D 2 receptor occupancy levels were 41-43 % for 10 mg, 51-55 % for 20 mg, 63-67 % for 40 mg, 77-84 % for 60 mg, and 73-79 % for 80 mg of lurasidone. The relationship between D2 receptor occupancy and the mean serum lurasidone concentration during the PET scan (C PET) was similar for the putamen, caudate nucleus, and ventral striatum regions. Mean D2 receptor occupancy levels correlated well with average peak serum concentration of lurasidone. Conclusions: In healthy volunteers, single doses of lurasidone 40-80 mg resulted in D2 receptor occupancy levels of >60 %, a level of receptor occupancy previously associated with clinical response for atypical antipsychotics.
AB - Rationale: A positron emission tomography (PET) study of dopamine D 2 receptor occupancy was conducted to support a rational dose selection for clinical efficacy studies with lurasidone, an atypical antipsychotic that was approved for the treatment of schizophrenia by the FDA in late 2010. Objectives: To determine the dopamine D2 receptor occupancy of lurasidone in the ventral striatum, putamen and caudate nucleus, and to characterize the relationship between lurasidone serum concentration and D2 receptor occupancy. Methods: A single oral dose of lurasidone (10, 20, 40, 60, or 80 mg) was administered sequentially to healthy male subjects (n = 4 in each cohort). Two PET scans were performed. For each scan, 20 mCi of [11C]raclopride was administered intravenously as a bolus injection, followed immediately by 90 min of PET scan acquisitions. Results: The D 2 receptor occupancy levels were 41-43 % for 10 mg, 51-55 % for 20 mg, 63-67 % for 40 mg, 77-84 % for 60 mg, and 73-79 % for 80 mg of lurasidone. The relationship between D2 receptor occupancy and the mean serum lurasidone concentration during the PET scan (C PET) was similar for the putamen, caudate nucleus, and ventral striatum regions. Mean D2 receptor occupancy levels correlated well with average peak serum concentration of lurasidone. Conclusions: In healthy volunteers, single doses of lurasidone 40-80 mg resulted in D2 receptor occupancy levels of >60 %, a level of receptor occupancy previously associated with clinical response for atypical antipsychotics.
KW - Antipsychotic agents
KW - Dopamine D receptors
KW - Dose-response relationship
KW - Drug
KW - Lurasidone
KW - Positron emission tomography
UR - http://www.scopus.com/inward/record.url?scp=84883456045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883456045&partnerID=8YFLogxK
U2 - 10.1007/s00213-013-3103-z
DO - 10.1007/s00213-013-3103-z
M3 - Article
C2 - 23649882
AN - SCOPUS:84883456045
SN - 0033-3158
VL - 229
SP - 245
EP - 252
JO - Psychopharmacology
JF - Psychopharmacology
IS - 2
ER -